F90.0
Conditions
Interventions
Group 1: Patients with a confirmed diagnosis of adult ADHD who receive pharmacotherapy as part of regular outpatient care. Treatment is not determined by the study. Symptoms, functional level, tolerab
Sponsors
Praxis Dr. Klinga
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Confirmed diagnosis of ADHD in adulthood according to ICD-10/DSM-5 - Start of regular treatment at Praxis Dr. Klinga as part of routine care, e.g. pharmacotherapy and/or group therapy - Sufficient German or English language skills to participate in diagnostics, treatment, and questionnaire assessments - Capacity to provide informed consent - Written informed consent to participate in the study after prior information and explanation
Exclusion criteria
Exclusion criteria: - Lack of capacity to provide informed consent or refusal to provide written informed consent - Severe cognitive impairment or language barriers that make reliable participation in diagnostics and treatment impossible - Current acute psychotic symptoms, florid mania, or suicidal crisis requiring inpatient treatment - No regular treatment at Praxis Dr. Klinga, e.g. only a one-time diagnostic assessment without further contact
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: Change in ADHD symptom severity and impairment relevant to daily life over time. This parameter is assessed at T0 = baseline and subsequently every 6 months, i.e. T1 = 6 months, T2 = 12 months, T3 = 18 months, etc. Assessment is performed using the digital, study-specific ARCADIA self-assessment questionnaire on ADHD core symptoms and impairment relevant to daily life | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: - Change in functional level in work/occupation, social functioning, and daily organization - Patient-reported treatment satisfaction - Adherence and course of treatment - Tolerability and medication-related side effects - Treatment discontinuation and reasons for discontinuation Data are collected continuously during the observational period and evaluated at the respective 6-month time points. Assessment is based on patient-reported information from the digital ARCADIA self-assessment questionnaire as well as pseudonymized routine data from the patient record, including documented reasons such as lack of efficacy, side effects, or organizational reasons | — |
Countries
Germany
Contacts
Public ContactAndreas Krogner
Praxis Dr. Klinga
Outcome results
None listed